The PCN however recommends Anoro Ellipta® for the treatment of COPD in line with the positioning of LAMA/LABA in the management of COPD pathway. This product or device has not been included within the locally agreed list of preferred treatment options for COPD. Umeclidinium & vilanterol (Anoro Ellipta ®)įor preferred device selection, see Chapter links section above The nebuliser and ongoing consumables are supplied direct to the patients home by Philips Respironics Nebules: A pathway has been agreed for the use of home nebulised therapy in specific cohorts of patients. Ipratropium bromide with salbutamol (Combivent ®) This is the preferred device in patients unable to use DPI. If an alternative device is necessary consider the Spiolto Respimat (tiotropium with olodaterol) soft mist inhaler. Tiotropium & olodaterol ® (Spiolto Respimat ®) Glycopyrrolate/ indacaterol inhaler (Ultibro Breezhaler ®) Long Acting Muscarinic Antagonist (LAMA)/Long Acting Beta2- Agonists (LABA)ĭuaklir Genuair (aclidinium with formoterol) DPI and Ultibro Breezhaler (Glycopyrronium with indacaterol) DPI are the locally agreed LAMA/LABAs of choice. PRESCRIBE BY BRAND - For preferred device selection, see Chapter links section above NICE NG80 - Asthma: diagnosis, monitoring and chronic asthma managementĪclidinium and formoterol inhaler (Duaklir Genuair ®) NICE NG115 - COPD in over 16s - diagnosis and management NICE TA38: Asthma inhaler devices (older children)Īsthma Guidelines Preferred Inhaler Devices Feb 2017ĬOPD Guidelines - Preferred Inhaler Devices Feb 2017 NICE TA10: Asthma inhaler devices (children under 5) Please refer to individual SPCs for the current expiry details. Some inhaler devices now require fridge storage until opened or have reduced expiry once in use.Spacer devices are recommended for use with Metered Dose Inhalation (MDI) devices.The use of High Dose Inhaled Corticosteroid (ICS) Safety Cards are recommended for use as appropriate The Primary Care Asthma Management Guidelines were approved by the PCN.If any doubt exists the patient should be consulted in order to identify which brand of inhaler they currently use in order to maintain current treatment. Inhalers should be prescribed by brand name to prevent confusion and dispensing/administration errors, thereby maintaining continuity of care.Guildford And Waverley Joint Formulary Guildford & Waverley ICPįormulary Chapter 3: Respiratory system - Full Chapter Guildford And Waverley Joint Formulary Formulary
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |